Ocumension Therapeutics H1 revenue jumps on higher ophthalmic sales
Ocumension Therapeutics said its H1 revenue surged, citing higher ophthalmic product sales.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.